Reproductive Health Care Training Act of 2026

Stop Anti-Abortion Disinformation (SAD) Act (S. 589/H.R. 846) Abortion Care Awareness Act (H.R. 2497) OPPOSE: Born-Alive Abortion Survivors Protection Act (H.R. 21/S. 6) OPPOSE: Repeal of the FACE Act (H.R. 589) EACH Act (H.R. 4611/S. 2377) OPPOSE: Supporting Pregnant and Parenting Women and Families Act (H.R. 6945) OPPOSE: Nonprofit status of abortion funds (H.R. 7286) Providing for congressional disapproval under chapter 8 of title 5, United States Code, of the rule submitted by the Department of Veterans Affairs relating to "Reproductive Health Services" (H.J. Res 144 /S.J. 103 ) Abortion Provider Appreciation Day Resolution (S Con Res. 28/H Con Res. 78) Reproductive Health Care Training Act (H.R. 9420/S. 4878) Let Doctors Provide Reproductive Health Act (S. 4879) The Freedom to Travel for Health Care Act (S. 4701) Reproductive Health Travel Fund Act (H.R. 4625/S. 4922) Resolution Regarding the Safety of Mifepristone (S. Res. 732/H. Res. 1285)

Client expense: $17,436 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Right to Contraception Act (S. 422/H.R. 999) A resolution expressing the sense of the Senate that over 25 years of real-world evidence and hundreds of peer-reviewed studies proving that mifepristone is safe and effective should be respected, and law and policy governing access to lifesaving, time-sensitive medication abortion care in the United States should be equitable, transparent, and based on the best available peer-reviewed evidence-based science. (S.J. Res. 732) Expressing the sense of the House of Representatives that over 25 years of real-world evidence and hundreds of peer-reviewed studies proving that mifepristone is safe and effective should be respected, and law and policy governing access to lifesaving, time-sensitive medication abortion care in the United States should be equitable, transparent, and based on the best available peer-reviewed evidence-based science. (H.J. Res. 1285) EACH Act (S. 2377/H.R. 4611) Right to IVF Act (not yet introduced) FACE Act Repeal Act (H.R. 589) Reproductive Health Care Accessibility Act (H.R. 8829/S. 4540) To express the Sense of Congress with respect to safety of medication abortion and Federal preemption of State restrictions on dispensing medication abortion, and for other purposes. (H.R. 8734) Freedom to Travel for Health Care Act of 2026 (S. 4701) SAFE Training for OBGYNs Act (H.R. 9441) Let Doctors Provide Reproductive Health Care Act (S. 4879/H.R. 9445) Reproductive Health Travel Fund Act of 2026 (S. 4922) Reproductive Health Care Training Act (S. 4878) Expressing the sense of the House of Representatives that the monitoring and regulation of water systems not be weaponized for the purposes of surveilling, tracking, or detecting use of, stigmatizing, and further restricting access to medication abortion care. (H.Res.1389) SAFER Health Act of 2026 (S. 4920/H.R. 9470)

Client expense: $652,972 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Abortion access (general); Access to mifepristone (general); Contraception (general); Maternal mortality and morbidity (general); H.R. 8651/S. _____, Advancing Safe Medications for Moms and Babies Act; Obstetric and gynecologic care in rural and underserved areas (general); impact of closures of labor and delivery units in rural hospitals on patient access to care and maternal morbidity and mortality; abortion training in obstetrics and gynecology residency programs (general); Teaching Health Center Graduate Medication Education program (general); implementation of P.L. 119-21, One Big, Beautiful Bill Act; implementation of Sec. 6501 of P.L. 119-75, Preventing Maternal Deaths Reauthorization Act; Telemedicine (general); S. 380/H.R. 1254, Rural Obstetrics Readiness Act; S. 1834/H.R. 3762, Supporting Healthy Moms and Babies Act; H.R. 7973, Momnibus Act; H.R. 7830, WELLS Act; H.R.8159, Gynecologic Pain Management Study Act; H.R.8160, Premenstrual Dysphoric Disorder Awareness and Research Act; H.R. 9441, SAFE Training for OBGYNs Act; H.R. 9061, PREEMPT Act; H.Res. 1282, a resolution recognizing ACOGs 75th anniversary; H.R. 8358, Breast Cancer Research Stamp Reauthorization Act; S. Res. 710, a resolution recognizing Maternal Mental Health Day; H.R. 9090/S. 4503, Advancing Menopause Care and Mid-Life Womens Health Act; H.Res. 1323, a resolution recognizing National Menstrual Health Awareness Month; H.R. 8500, Timely Access to Coverage Decisions Act; H.R. 7694, Gwenns Law; S. 4878, Reproductive Health Care Training Act; H.R. _____/S. _____, Right to IVF Act; S. 4494, America Cures Act; maternal mortality review committees (general); Patient-physician relationship (general); Obstetrician-gynecologist workforce (general); Substance use disorder during pregnancy (general); Maternal mental health (general); Insurance coverage for infertility (general); Protections for in vitro fertilization (general); Vaccination (general); childhood vaccine recommendations (general); Task Force on Research Specific to Pregnant Women and Lactating Women (PRGLAC) recommendations (general); inclusion of pregnant and lactating women in clinical trials (general); pregnancy exposure registries (general); NIH/NICHD womens health research (general); access to fertility services and treatments (general); Restorative Reproductive Medicine (general); Advisory Committee on Immunization Practices (ACIP); COVID vaccine during pregnancy (general); S. 4550/H.R. 8807, Maternal Health Pandemic Response Act; United States Preventive Services Taskforce (general); hormone therapy for menopause symptoms (general); acetaminophen use during pregnancy (general); SSRI use during pregnancy (general); Pregnancy Risk Assessment Monitoring System (PRAMS); Maternal Mortality Review Information Application (MMRIA); FACE Act implementation; Nexplanon REMS; chaperones during sensitive procedures (general); FDA regulation of flavored e-cigarettes (general); ORR policies regarding pregnant minors (general); breast cancer risk assessment (general).

Client expense: $96,000 · Firm income: Not reported

Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE